Nelson Mullins partner John Claud was quoted in a recent New York Times article examining the Food and Drug Administration’s anticipated move to lift restrictions on certain peptides. Drawing on his prior experience at the U.S. Department of Justice working with the FDA handling cases involving compounding pharmacies, Claud offered perspective on safety concerns surrounding these products.

“What I’ve seen are the people who would profit the most from this saying that these drugs are safe,” Claud said. “And what I haven’t seen is safety data that would tell me that these drugs should be more available.”  

Read the full article here.